A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database
Cancer Medicine · 2026-04 · 15 (4)
DOI: 10.1002/cam4.71527 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 30.03.2026. Verfasst von Boyi Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical College, Changsha Medical University, Changsha, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Adverse Drug Reaction Reporting Systems, Antineoplastic Combined Chemotherapy Protocols, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hunan Provincial Department of Education Fund Project, National Undergraduate Innovation and Entrepreneurship Training Program 2024 (Letter No. 13 [2024] from the Department of Higher Education), The "14th Five-Year Plan" Applied Characteristic Discipline of Hunan Province.
Abstract (Originalsprache)
Objective
Immune checkpoint inhibitors (ICIs) combined with platinum‐based compounds are commonly used in the treatment of certain malignant tumors. This study aims to analyze adverse events (AEs) associated with the combination therapy of ICIs and platinum‐based compounds by using the FAERS database.
Methods
This study retrieved relevant adverse event (AE) data from the FAERS database (2008–2024) and conducted a retrospective analysis of the collected AEs. Multiple disproportionality analysis algorithms were employed, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi‐item Gamma Poisson Shrinker (MGPS).
Results
Analysis of 28,585 reports identified 27 significant SOC‐level signals, strongest for hematological (ROR = 6.3), endocrine (ROR = 14.3), and hepatobiliary disorders (ROR = 4.49). Key PTs included malignant neoplasm progression (ROR = 16), febrile neutropenia (ROR = 15.31), and myocarditis (ROR = 16.3). 45.5% of AEs occurred within 1 month (median onset: 38 days). Combination therapy showed lower rates vs. monotherapy for malignancy progression and nephrotoxicity, but higher neurotoxicity (628 neuropathy cases).
Conclusion
The combination exhibits distinct early‐onset toxicities (early‐onset hematological/endocrine/hepatic) and novel risks (neuropathy/myocarditis/leukemia), necessitating enhanced initial monitoring and subgroup‐specific management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Clinical College, Changsha Medical University, Changsha, China.
- Institute of Cytology and Genetics, Basic Medical School, University of South China, Hengyang, China.
- Changsha Hospital for Maternal & Child Health Care, Changsha, China.
- Department of Basic Medical Sciences, Changsha Medical University, Changsha, Hunan, China.
- Hunan Provincial University Key Laboratory of the Fundamental and Clinical Research on Functional Nucleic Acid, Changsha, China.
ORCID-Profile: Boyi Liu, Ruizhe Huang
Förderung
- Hunan Provincial Department of Education Fund Project
- National Undergraduate Innovation and Entrepreneurship Training Program 2024 (Letter No. 13 [2024] from the Department of Higher Education)
- The "14th Five-Year Plan" Applied Characteristic Discipline of Hunan Province
- Changsha Outstanding Youth Innovation Talent Development Program
- The 2024 Hunan Provincial Student Innovation and Entrepreneurship Training Program Project, Xiang- jiaotong [2024] 191 - General Project - 5276
- Natural Science Founda- tion of Hunan Province
Zitieren
APA
Liu, B., Zhang, W., Huang, R., Liu, D., Liu, J., Han, A., Li, Y., & Chen, D. (2026). A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71527
Vancouver
Liu B, Zhang W, Huang R, Liu D, Liu J, Han A, et al. A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71527
BibTeX
@article{Liu2026,
author = {Liu, Boyi and Zhang, Wenchao and Huang, Ruizhe and Liu, Dinwen and Liu, Jiaxing and Han, Ao and Li, Yike and Chen, Danna},
title = {A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/cam4.71527}
}
EUVIMED